Kang H - Search Results

1

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy.

Soares F, Chen B, Lee JB, Ahmed M, Ly D, Tin E, Kang H, Zeng Y, Akhtar N, Minden MD, He HH, Zhang L. Soares F, et al. Among authors: kang h. Blood. 2021 Apr 22;137(16):2171-2181. doi: 10.1182/blood.2019004108. Blood. 2021. PMID: 33270841 Free article.

2

Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.

Lee J, Minden MD, Chen WC, Streck E, Chen B, Kang H, Arruda A, Ly D, Der SD, Kang S, Achita P, D'Souza C, Li Y, Childs RW, Dick JE, Zhang L. Lee J, et al. Among authors: kang s, kang h. Clin Cancer Res. 2018 Jan 15;24(2):370-382. doi: 10.1158/1078-0432.CCR-17-2228. Epub 2017 Oct 26. Clin Cancer Res. 2018. PMID: 29074605 Free PMC article.

3

Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy.

Chen B, Lee JB, Kang H, Minden MD, Zhang L. Chen B, et al. Among authors: kang h. J Exp Clin Cancer Res. 2018 Apr 24;37(1):88. doi: 10.1186/s13046-018-0756-9. J Exp Clin Cancer Res. 2018. PMID: 29690909 Free PMC article.

4

Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.

Lee JB, Khan DH, Hurren R, Xu M, Na Y, Kang H, Mirali S, Wang X, Gronda M, Jitkova Y, MacLean N, Arruda A, Alaniz Z, Konopleva MY, Andreeff M, Minden MD, Zhang L, Schimmer AD. Lee JB, et al. Among authors: kang h. Blood. 2021 Jul 22;138(3):234-245. doi: 10.1182/blood.2020009081. Blood. 2021. PMID: 34292323 Free PMC article.

5

Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer.

Lee JB, Kang H, Fang L, D'Souza C, Adeyi O, Zhang L. Lee JB, et al. Among authors: kang h. Clin Cancer Res. 2019 Apr 1;25(7):2241-2253. doi: 10.1158/1078-0432.CCR-18-2291. Epub 2019 Jan 7. Clin Cancer Res. 2019. PMID: 30617140

6

Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15.

Yao J, Ly D, Dervovic D, Fang L, Lee JB, Kang H, Wang YH, Pham NA, Pan H, Tsao MS, Zhang L. Yao J, et al. Among authors: kang h. J Immunother Cancer. 2019 Jan 22;7(1):17. doi: 10.1186/s40425-019-0507-2. J Immunother Cancer. 2019. PMID: 30670085 Free PMC article.

7

Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade.

Fang L, Ly D, Wang SS, Lee JB, Kang H, Xu H, Yao J, Tsao MS, Liu W, Zhang L. Fang L, et al. Among authors: kang h. J Exp Clin Cancer Res. 2019 Mar 11;38(1):123. doi: 10.1186/s13046-019-1126-y. J Exp Clin Cancer Res. 2019. PMID: 30857561 Free PMC article.

8

[No title available]

[No authors listed] [No authors listed] PMID: 33728465

9

State-of-Art of Cellular Therapy for Acute Leukemia.

Lee JB, Vasic D, Kang H, Fang KK, Zhang L. Lee JB, et al. Among authors: kang h. Int J Mol Sci. 2021 Apr 27;22(9):4590. doi: 10.3390/ijms22094590. Int J Mol Sci. 2021. PMID: 33925571 Free PMC article. Review.

10

Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib.

Kang H, Lee JB, Khatri I, Na Y, D'Souza C, Arruda A, Minden MD, Zhang L. Kang H, et al. Cancers (Basel). 2021 Oct 9;13(20):5039. doi: 10.3390/cancers13205039. Cancers (Basel). 2021. PMID: 34680188 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16,369 results

Search Page